Ladanyi M, Traganos F, Huvos A G
Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021.
Cancer. 1989 Oct 1;64(7):1521-6. doi: 10.1002/1097-0142(19891001)64:7<1521::aid-cncr2820640727>3.0.co;2-7.
Approximately 2% of histologically benign giant cell tumors (BGCT) of bone are complicated by lung metastases, which can progress despite their benign histologic appearance. Almost all BGCT studied by DNA flow cytometry (FCM) have been reported to be diploid. However, the very few cases with lung metastases previously analyzed were all aneuploid. To assess the usefulness of DNA FCM in predicting the metastatic potential of BGCT, seven metastasizing BGCT were studied by DNA FCM using paraffin-embedded tissue. Five were purely diploid, one was tetraploid, and one was aneuploid. The primary and the metastasis showed the same DNA distribution in all but the tetraploid case, in which the metastasis was purely diploid. A single patient, who was in the diploid group, had unresectable tumor in the lungs; she remains alive with stable disease at 30 months. The other six patients, who underwent complete resections of their lung metastases, are free of disease. These results suggest that DNA FCM is not a sensitive method for predicting the metastatic potential of BGCT since most metastasizing cases appear to be diploid.
约2%的组织学良性骨巨细胞瘤(BGCT)会并发肺转移,尽管其组织学表现为良性,但仍可能进展。几乎所有通过DNA流式细胞术(FCM)研究的BGCT均报告为二倍体。然而,之前分析的极少数有肺转移的病例均为非整倍体。为评估DNA FCM在预测BGCT转移潜能方面的作用,我们使用石蜡包埋组织通过DNA FCM对7例发生转移的BGCT进行了研究。其中5例为纯二倍体,1例为四倍体,1例为非整倍体。除四倍体病例外,其余病例的原发肿瘤和转移灶显示出相同的DNA分布,四倍体病例的转移灶为纯二倍体。二倍体组中有1例患者肺部肿瘤无法切除;30个月时她仍存活,病情稳定。其他6例接受了肺转移灶完整切除的患者均无疾病。这些结果表明,DNA FCM不是预测BGCT转移潜能的敏感方法,因为大多数发生转移的病例似乎是二倍体。